BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and ...

Larimar Therapeutics Inc (LRMR) stock saw a modest uptick, ending the day at $7.14 which represents a slight increase of $0.29 or 4.23% from the prior close of $6.85. The stock opened at $7.08 and ...

Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Fintel reports that on September 12, 2024, Jones Trading initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a ...

Ataxia Market Set To Witness Significant Growth By 2024-2031: Pfizer, Inc., CRISPR Therapeutics, Sanofi, Bio-Techne Ataxia market is estimated to be valued at US$ 30,880.5 million in 2024 and is ...

Larimar Therapeutics Inc (LRMR) stock saw a decline, ending the day at $8.05 which represents a decrease of $-0.85 or -9.55% from the prior close of $8.9. The stock opened at $8.92 and touched a low ...

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR) today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support ...

Baird has initiated coverage on Larimar Therapeutics (NASDAQ: LRMR) with an Outperform rating and set a price target of $16.00. The firm's optimism is anchored in the potential U.S. approval of ...

The stock price of Larimar Therapeutics Inc (NASDAQ: LRMR) has dropped by -12.52 compared to previous close of 7.91. Despite this, the company has seen a fall of -13.39% in its stock price over the ...